US SEC Filings Daily Market Digest — October 01, 2026

01-10-2026

TotalEnergies SE filed a Form 6-K covering a series of September 2026 developments, including the completion of its entry as operator into Namibia's PEL83 license (Mopane discovery), a Final Investment Decision for the Absheron full field development in Azerbaijan, and a new discovery on Block 17 in Angola. The company also announced leadership changes, a partnership with Mistral AI, and reaffirmed its strategy and governance confidence. While the filing highlights multiple growth initiatives, it also includes routine share buyback disclosures and no explicit financial performance metrics, so the overall sentiment is neutral-to-positive.

• · Exhibit 99.1-99.16 list 16 separate disclosures, including four share buyback disclosures (September 1, 8, 15, 22, 29).
• · The filing includes a Strategy and Outlook Presentation 2026 (September 28, 2026).
• · The Board of Directors reaffirmed the company's strategy and confidence in governance on September 25, 2026.
• · TotalEnergies became sole owner of the Grandpuits advanced plastics recycling plant on September 11, 2026.
• · The company signed an agreement with GIP on African energy infrastructure assets on September 18, 2026.

01-10-2026

Magnolia Oil & Gas provided an interim update after closing the WildFire Energy acquisition, reporting Q3 2026 production of 116-118 Mboe/d and Q4 2026 guidance of 159-161 Mboe/d. Net debt ended Q3 at ~$1.9B (below 1.0x net debt/EBITDA), ahead of schedule. However, the company sold non-core assets (1.4 Mboe/d) and expects one-time integration costs of $65-75M in Q3, while D&C capex rises to ~$235M in Q4. Organic growth is guided at 4-5% for 2027, above peer average, but leverage reduction and share repurchases (at least 1% per quarter) remain priorities.

• · Q3 2026 D&C capital spending expected between $155M and $165M.
• · Q4 2026 LOE guidance $5.80-$6.20 per Boe; GP&T $1.80-$2.10 per Boe; DD&A $14.00-$15.00 per Boe.
• · Production and ad valorem taxes 5.5%-6.5% of revenue; interest expense $35M-$40M in Q4 2026.
• · Effective tax rate ~21%; cash tax rate 0%-2%.
• · Pre-hedge oil realization differential to MEH of $(2.00) per barrel.
• · Magnolia added costless collar hedges with weighted average floor prices ranging $70.00-$73.75/Bbl and ceilings $80.08-$98.09/Bbl through Q4 2027.
• · Inherited WildFire hedges include crude oil swaps with weighted average prices $63.46-$67.37/Bbl through Q4 2027.
• · More than half of oil production hedged through Q2 2027.
• · 2027 production growth of 4-5% off Q2 2026 pro forma base of 78 Mbo/d oil and 158 Mboe/d total.
• · 2027 D&C capex $900M-$950M includes modest oil field service inflation.

01-10-2026

Innovative Industrial Properties (IIPR) announced a $245 million mezzanine loan commitment for Alewife Park, a life science campus in Cambridge, MA, expected to yield 15.8% and generate significant earnings accretion. IIP funded $111 million at closing, with the remaining $134 million to be funded through Q4 2027. The loan matures in February 2028 with a one-year extension option, and IIP may increase its investment by up to $155 million on the same terms. The investment diversifies IIP's portfolio into the life science sector, but carries risks related to development, lease-up, and interest rate fluctuations.

• · The loan is secured by pledges of equity interests in the entities that own the Alewife Park campus.
• · Phase I is currently 78% leased to Lila Sciences, an AI-enabled scientific discovery company.
• · The loan matures in February 2028 with a one-year extension option.
• · IIP may purchase up to $155 million of other mezzanine lender's notes on the same terms.
• · IIP expects to fund the investment with cash on hand and borrowings under its revolving credit facilities.

01-10-2026

American Vanguard Corporation (AVD) announced a planned CFO transition, with Matt Horwath joining as CFO effective October 1, 2026, succeeding David Johnson. Johnson will remain as Chief Accounting Officer until March 2027 and continue in a non-executive role until September 2027. The change is part of a leadership transition aimed at driving financial discipline, capital allocation, and operational performance.

• · David Johnson served as CFO for 18 years, guiding AVD through growth and global expansion including acquisitions in Latin America, Australia, and biologicals.
• · Matt Horwath brings nearly 20 years of finance and public company leadership experience, most recently as CFO of Kustom US, Inc., and previously as SVP and CFO of FARO Technologies, Inc., where he helped lead a strategic transformation culminating in its acquisition by AMETEK in 2025.
• · Horwath is a Certified Public Accountant and holds a Master of Accountancy from the University of North Florida and a BBA in Accounting from the University of Central Florida.
• · Johnson will assist as Chief Accounting Officer until March 2027, then continue in a non-executive position until September 2027.

01-10-2026

Chesapeake Utilities Corporation (NYSE: CPK) announced on October 1, 2026, the establishment of a $225 million at-the-market (ATM) equity offering program to sell common stock from time to time. The ATM Program, effective immediately, will use proceeds for general corporate purposes including capital expenditures, debt repayment, and potential acquisitions. The offering is being made under the company's existing Form S-3 shelf registration statement, with sales conducted through multiple managers and forward sellers.

• · The ATM Program is established under the company's existing shelf registration statement on Form S-3 (File No.: 333-299198).
• · Sales may be made directly on or through the New York Stock Exchange as 'at-the-market offerings' under Rule 415.
• · Forward Purchasers may borrow and sell shares to hedge forward sale agreements.
• · Proceeds intended for general corporate purposes including financing capital expenditures, repaying short-term debt or revolving credit borrowings, financing acquisitions, investing in subsidiaries, and working capital.
• · Prospectus supplement available free from Barclays Capital Inc. or via SEC's EDGAR website.

01-10-2026

Monte Rosa Therapeutics announced positive Phase 1 results for MRT-8102, a NEK7-directed molecular glue degrader, in the GFORCE-1 study. The drug achieved robust NEK7 degradation (median 80-90% reduction) and reduced key pathogenic drivers of ASCVD, including a 24% reduction in median lipoprotein(a), without increasing LDL-C or triglycerides. The company plans to initiate multiple Phase 2 studies in H1 2027, including GFORCE-2 (coronary artery disease), GEMINI-1 (gout), and GALAXY-1 (hidradenitis suppurativa).

• · MRT-8102 was administered at 5 mg, 20 mg, or 40 mg once daily for 4 weeks with 4 weeks follow-up.
• · No serious adverse events (SAEs) were reported.
• · TEAE rates were similar between MRT-8102 (33%) and placebo (30%), with no evidence of increased infection risk.
• · GFORCE-2 (Phase 2b) is expected to initiate in H1 2027 and will evaluate changes over a six-month dosing period.
• · GEMINI-1 (Phase 2, gout) is expected to initiate in Q4 2026 or Q1 2027 with initial data expected in H2 2027.
• · GALAXY-1 (Phase 2, hidradenitis suppurativa) is expected to initiate in H1 2027.

01-10-2026

Valion Bio, Inc. (Nasdaq: VBIO), formerly Tivic Health Systems, Inc., announced on September 30, 2026, the successful completion of formulation work with Shear Kershman Laboratories to develop a novel oral mucosal formulation of Entolimod, its lead drug candidate for Acute Radiation Syndrome (ARS). The company highlighted the potential for a needle-free delivery method to expand the addressable market, estimating 10 to 40 times the doses of its injectable program, though it cautioned this is not a revenue forecast. However, the filing includes no financial results, and the development remains subject to regulatory approval and further studies, with significant risks and uncertainties noted.

• · The oral mucosal formulation could require approximately 10 to 40 times the number of doses compared to the injectable program, assuming supply to 2.0 million service members, 1.0 million firefighters, and 790,000 law enforcement officers.
• · Entolimod is being developed under the FDA's Animal Rule, which allows approval based on animal efficacy studies when human trials are not ethical or feasible.
• · No treatment is currently approved for the gastrointestinal form of Acute Radiation Syndrome (ARS).
• · Entolasta is a next-generation TLR5 agonist being developed for broader therapeutic applications, including oncology supportive care.

01-10-2026

Chairman - CEO GRINBERG EFRAIM was awarded 471.05 Phantom Stock Unit.

• · Chairman - CEO GRINBERG EFRAIM was awarded 471.05 Phantom Stock Unit

01-10-2026

Woodward Financial Advisors, Inc. filed its Form 13F-HR for the quarter ended June 30, 2024, reporting total holdings of approximately $175.6 million across 51 equity positions. The portfolio is heavily weighted toward Dimensional ETF Trust funds (e.g., US High Profitability, International Core Equity, Short Duration Fixed Income) and iShares core ETFs, with top individual stock holdings in Apple, Microsoft, and Berkshire Hathaway. The filing reflects a diversified, ETF-centric strategy with a focus on value, small-cap, and international exposure.

• · Top 5 holdings by value: iShares Core S&P 500 ETF ($32.9M), Vanguard Short-Term Inflation-Protected Securities Index ($16.2M), Dimensional International Core Equity ETF ($13.2M), Dimensional Short Duration Fixed Income ETF ($10.6M), and Dimensional US Marketwide Value ETF ($6.1M).
• · Largest single stock positions: Apple ($2.38M), Microsoft ($1.80M), Berkshire Hathaway Class A ($1.83M), and JPMorgan Chase ($1.05M).
• · The portfolio includes 34 ETFs and 17 individual stocks, with ETFs representing approximately 88% of total value.
• · No period-over-period comparisons are available as this is a standalone filing without prior quarter data.

01-10-2026

Director West Tony was awarded 388.64 Phantom Stock Units at $61.11 (~$23.7K).

• · Director West Tony was awarded 388.64 Phantom Stock Units at $61.11 (~$23.7K)

01-10-2026

Director Ji Ping sold 5,000 American Depository shares at $16.03 (~$80.2K). Ji Ping holds 121,453 shares after the transaction.

• · Director Ji Ping sold 214 American Depository shares at $15.77 (~$3.37K)
• · Director Ji Ping sold 5,000 American Depository shares at $16.03 (~$80.2K)
• · Director Ji Ping sold 5,000 American Depository shares at $15.95 (~$79.8K)

01-10-2026

Director Chartier Kirk was awarded 782 Phantom Stock.

• · Director Chartier Kirk was awarded 782 Phantom Stock

01-10-2026

PolyPid Ltd. announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for D-PLEX₁₀₀, initiating formal review for the prevention of post-abdominal surgery incisional infections. The MAA was submitted on September 14, 2026 under the Centralized Procedure. Concurrently, the FDA has accepted the NDA for D-PLEX₁₀₀ under Priority Review with a PDUFA goal date of November 28, 2026. The application is supported by the positive Phase 3 SHIELD II trial which demonstrated a 60% relative risk reduction in surgical site infections (p=0.0013). No negative or flat metrics were reported in this filing.

• · MAA submitted on September 14, 2026 under the Centralized Procedure based on therapeutic innovation.
• · Validation confirms the application is complete and initiates formal review by EMA's Committee for Medicinal Products for Human Use.
• · Productive meetings held with EMA Rapporteur and Co-Rapporteur during Q2 2026.
• · If approved, D-PLEX100 would receive a single marketing authorization valid throughout EU member states.
• · PolyPid retains commercial rights to D-PLEX₁₀₀ outside the U.S. and Canada; Azurity Pharmaceuticals is the partner for the U.S. and Canada.
• · D-PLEX₁₀₀ received Breakthrough Therapy Designation from the FDA for prevention of SSIs in elective colorectal surgery.

01-10-2026

Director Baird Gordon A bought 300 Common Stock at $4.89 (~$1.47K). Baird Gordon A holds 300 shares after the transaction.

• · Director Baird Gordon A bought 300 Common Stock at $4.89 (~$1.47K)

01-10-2026

Director Ferruzzi Mario was awarded 42.304 Deferred Stock.

• · Director Ferruzzi Mario was awarded 42.304 Deferred Stock

01-10-2026

Director MILLER DAVID B was awarded 51.031 Restricted Stock Unit.

• · Director MILLER DAVID B was awarded 51.031 Restricted Stock Unit

01-10-2026

Director Morabito Paula was awarded 5,755 Deferred Stock Units.

• · Director Morabito Paula was awarded 5,755 Deferred Stock Units

01-10-2026

Director RITOTA JOHN was awarded 5,860 Common Stock. RITOTA JOHN holds 47,215 shares after the transaction.

• · Director RITOTA JOHN was awarded 5,860 Common Stock

01-10-2026

Director King Terri Gay was awarded 4 Deferred Share Unit.

• · Director King Terri Gay was awarded 4 Deferred Share Unit

01-10-2026

WPP plc announced it will release its Q3 2026 Trading Update on October 29, 2026, with a conference call for investors and analysts. The filing is a routine notification of the upcoming earnings event and contains no financial results or performance data.

• · Q3 2026 Trading Update covers the three and nine months ended September 30, 2026.
• · Conference call scheduled for October 29, 2026 at 9:00 AM BST.
• · Webcast available at www.wpp.com/investors.

01-10-2026

Form 4 ownership filing; the structured EDGAR document could not be retrieved for automated parsing.

01-10-2026

Pyxis Oncology, Inc. completed an underwritten public offering on October 1, 2026, raising approximately $102.8 million in net proceeds by selling shares, pre-funded warrants, and common warrants. The company plans to use the funds to advance its lead clinical program MICVO, including a planned Phase 3 trial, and expects its cash runway to extend into the first half of 2028. However, the common warrants are not exercisable until stockholder approval is obtained to increase authorized shares, and if not exercised, the net proceeds plus existing cash will not fully fund the Phase 3 trial.

• · The offering closed on October 1, 2026.
• · Common warrants expire 5 years after charter amendment effective date or 30 days after OS data release date, whichever is earlier.
• · OS data release expected in first half of 2027.
• · Company must hold stockholder meeting within 60 days of closing to seek charter amendment approval; if not obtained, additional meetings every 60 days.
• · If common warrants are not exercised, net proceeds plus existing cash will not fully fund the Phase 3 Headliner trial.
• · The registration statement on Form S-3 was filed on November 26, 2025 and declared effective on December 9, 2025.

01-10-2026

GP Brinson Investments LLC filed its quarterly 13F-HR report for the period ending September 30, 2026, disclosing 13 equity holdings with a total market value of approximately $234.1 million. The portfolio is heavily weighted toward Vanguard index funds, with the largest positions in Vanguard Total Stock Market ETF ($102.4M), Vanguard FTSE Developed Markets ETF ($45.5M), and Vanguard FTSE Emerging Markets ETF ($21.9M). The filing shows a diversified mix of U.S. and international equity ETFs, fixed-income ETFs, and select individual stocks such as Apple and Chipotle Mexican Grill.

• · All 13 holdings are reported with sole voting and investment authority; no shared or non-voting positions.
• · The portfolio includes exposure to U.S. equities (VTI), international developed markets (VEA), emerging markets equities (VWO), U.S. bonds (AGG), global real estate (REET), emerging market bonds (VWOB), long-term corporate bonds (VCLT), and single-stock positions in Apple, Chipotle, Enterprise Products Partners, and Blue Owl Capital.
• · The filing was signed by Timothy J. Dolan, Chief Investment Officer, on October 1, 2026.
• · No prior-period comparison data is available in this filing to assess changes in holdings.

01-10-2026

Watts Water Technologies announced the retirement of Kenneth R. Lepage, General Counsel, Chief Compliance Officer and Chief Sustainability Officer, effective March 31, 2027, after over 23 years of service. The company is initiating a search for his successor, and Lepage will remain in his roles to ensure an orderly transition. This is a routine leadership succession announcement with no immediate financial impact.

01-10-2026

Director Ryan Robert John Andrew bought 15,000 Common Stock at $2.68 (~$40.2K). Ryan Robert John Andrew holds 675,222 shares after the transaction.

• · Director Ryan Robert John Andrew bought 15,000 Common Stock at $2.68 (~$40.2K)

01-10-2026

Agassi Sports Entertainment Corp. (AASP) announced the hiring of Jonathan Fornaci as President of its newly formed wholly-owned subsidiary, Let's Play, LLC, to advance the global 'Let's Play' pickleball and padel facilities initiative. The initiative aims to pursue the acquisition, development, and operation of pickleball and padel facilities. No financial figures or performance metrics were disclosed in the filing.

• · The subsidiary Let's Play, LLC is a Nevada limited liability company recently formed as a wholly-owned subsidiary of Agassi Sports Entertainment Corp.
• · The press release is furnished as Exhibit 99.1 and contains forward-looking statements.

01-10-2026

Bowen Acquisition Corp reported net income of $1,090,307 for Q2 2026, up 45.3% from $750,303 in Q2 2025, driven by a $1,096,351 gain on settlement of FPA liability. However, formation and operating costs decreased 31.1% to $52,944, and interest earned on trust investments fell 32.4% to $59,806. For the six-month period, the company swung to a net income of $1,069,485 from a net loss of $1,289,691 in the prior year, though cash used in operations improved to -$8,187 from -$86,218.

• · The company's cash balance dropped 76.7% to $4,093 as of June 30, 2026, from $17,556 a year earlier.
• · Ordinary shares subject to possible redemption fell 71.5% to $2,190,570 from $7,673,771 at year-end 2025, reflecting $5,610,482 in redemptions.
• · The FPA liability gain of $1,096,351 was a non-recurring item that significantly boosted Q2 2026 net income.
• · Weighted average redeemable shares outstanding declined 24.6% YoY in Q2 (572,205 vs 759,249), and 49.7% in H1 (622,521 vs 1,238,013).
• · The company's accumulated deficit improved to -$1,428,482 as of June 30, 2026, from -$2,370,686 at the start of the year.
• · Probability of completion of business combination is estimated at 65.0%.

01-10-2026

Senior VP & CFO Beggs Jamie A. was awarded 45.8906 Phantom Stock Units at $104.33 (~$4.79K).

• · Senior VP & CFO Beggs Jamie A. was awarded 45.8906 Phantom Stock Units at $104.33 (~$4.79K)

01-10-2026

Non-Executive Chairman Jumper John P was awarded 1,125 Class A Common Stock. Jumper John P holds 35,581 shares after the transaction.

• · Non-Executive Chairman Jumper John P was awarded 1,125 Class A Common Stock

01-10-2026

Form 4 ownership filing; the structured EDGAR document could not be retrieved for automated parsing.

01-10-2026

Matthews International Corporation announced that long-serving directors Katherine E. Dietze and Morgan K. O'Brien will not stand for re-election at the 2027 Annual Meeting, supporting a board right-sizing initiative to reduce from ten to eight directors. The move builds on recent strategic actions including multiple divestitures, acquisitions, governance enhancements, and a restructuring expected to generate ~$10M in annual cost savings starting FY2027. While the company highlights board refreshment and strategic progress, the departures of two experienced directors and ongoing portfolio simplification signal a period of significant transition.

• · Since 2023, the Board has appointed five new directors with targeted skill sets in growth areas.
• · Divestitures completed: SGK Brand Solutions into Propelis JV (May 2025), European packaging business (Dec 2025), warehouse automation business (Dec 2025).
• · Acquisition of The Dodge Company, Inc. (embalming fluid company) in May 2025.
• · Effective August 31, 2026, Michael J. Whitehead succeeded long-time CEO Joseph C. Bartolacci.
• · Company operates two core global businesses: Industrial Technologies and Memorialization, plus a significant investment in Propelis.
• · Company has over 4,300 employees in 15 countries on four continents.

01-10-2026

NSTS Bancorp, Inc. completed its merger with Brookfield Bancshares, Inc. effective October 1, 2026, with shareholders receiving $14.31 per share in cash, totaling approximately $73.7 million. The company's common stock was delisted from Nasdaq, and the company ceased to exist as a separate entity. The merger was approved by shareholders with 3,762,060 votes for and only 3,905 against, representing 71.69% of outstanding shares.

• · The merger was approved by shareholders with 3,762,060 votes for and only 3,905 against, representing 71.69% of outstanding shares.
• · The company's common stock was delisted from Nasdaq, and the company ceased to exist as a separate entity.
• · The company's directors and executive officers ceased to hold their positions as of the Effective Time.
• · The Bank will continue to operate under its existing name and federal savings association charter as a subsidiary of Brookfield.
• · The company's Certificate of Incorporation and Bylaws ceased to be in effect by operation of law.
• · Brookfield intends to file a Form 15 with the SEC to deregister the common stock and suspend reporting obligations.

01-10-2026

Transcode Therapeutics (RNAZ) disclosed that its stock's daily VWAP fell below the $1.72 Floor Price for 10 out of 14 trading days from September 11 to September 30, 2026, triggering a potential Amortization Event under its convertible notes with Yorkville. To avoid default, the company made a $840,975 prepayment on October 1, 2026, covering $759,000 principal, a $75,900 prepayment premium, and $6,075 accrued interest, in exchange for a waiver of any Amortization Event through October 31, 2026. Following the prepayment, the aggregate principal outstanding under the convertible notes is approximately $4.1 million, down from $6.0 million originally advanced.

• · The Floor Price triggering an Amortization Event is $1.72 per share.
• · The prepayment waived any Amortization Event that occurred on or before September 30, 2026, and through October 31, 2026.
• · If an Amortization Event occurs, the company must make monthly payments equal to 18% of outstanding principal plus 10% premium plus accrued interest until the notes are repaid or the VWAP exceeds the Floor Price for 10 consecutive trading days.
• · The company's common stock trades on the Nasdaq Capital Market under the symbol RNAZ.

01-10-2026

Evolution Metals & Technologies Corp. (EMAT) announced a non-binding letter of intent with VIVIFY Technology for a strategic energy collaboration to deploy behind-the-meter hydrogen power for EMAT's planned U.S. rare earth magnet campus. The collaboration aims to secure domestic power for a critical materials supply chain, but the LOI is non-binding and subject to technical due diligence, definitive agreements, and regulatory approvals. No financial terms or definitive agreements have been reached, and there is no assurance the collaboration will proceed.

• · The LOI is non-binding and does not obligate either party to negotiate exclusively or enter into definitive agreements.
• · Any definitive agreements would be conditioned on satisfactory technical due diligence, independent validation of VIVIFY's systems, commercial terms, internal approvals, site control, and governmental/utility/environmental/safety authorizations.
• · EMAT's operating subsidiaries have more than 18 years of commercial magnet manufacturing history.
• · New DFARS sourcing requirements for the U.S. defense industrial base take effect on January 1, 2027.
• · VIVIFY's manufacturing in Jupiter, Florida is scheduled to begin in January 2027.
• · VIVIFY's system is designed to produce output that is 99% emission-free and does not require ongoing fuel resupply.

01-10-2026

Americas Carmart (CRMT) disclosed on September 30, 2026, that its lenders extended a temporary waiver of certain defaults and relief from minimum liquidity and collateral coverage ratio requirements through October 8, 2026. The company continues to evaluate strategic alternatives, including potential financing, recapitalization, or restructuring, but cautions there is no assurance of a favorable outcome. The filing highlights ongoing financial distress, with the company having experienced or anticipating events of default under its credit agreement, and warns that stockholders could experience a significant or complete loss of their investment.

• · The waiver and relief period has been extended multiple times since September 4, 2026, now through October 8, 2026.
• · The company has a special committee of the board overseeing the strategic review, which may include financing, recapitalization, restructuring, M&A, and other transactions.
• · The company explicitly warns that holders of common stock could experience a significant or complete loss of their investment.
• · The company may need to seek protection under bankruptcy or insolvency laws.
• · The company faces risks regarding continued listing on the Nasdaq Stock Market.

01-10-2026

AMC Robotics Corporation (Nasdaq: AMCI) announced the appointment of Dr. Ang Li as Chief Technology Officer, effective October 1, 2026. Dr. Li, an Assistant Professor at the University of Maryland, will lead the company's technology strategy and AI roadmap, focusing on autonomous intelligence, AI-powered perception, and edge computing. The appointment is part of AMC Robotics' strategy to strengthen AI integration in its robotics platforms, including its quadruped robot Kyro™ and warehouse sorting robot NovaArm™.

• · Dr. Li holds a Ph.D. in Electrical and Computer Engineering from Duke University and a Ph.D. from the University of Arkansas.
• · Dr. Li's research has been recognized with the NSF CAREER Award, Cisco Research Award, CPAL Rising Star Award, IEEE TCCPS Outstanding Ph.D. Dissertation Award, ACM KDD Best Student Paper Award, and Duke ECE Department Outstanding Dissertation Award.
• · Dr. Li will continue his academic role at the University of Maryland while serving as CTO.
• · The company's forward-looking statements include risks related to manufacturing facility buildout and production line commissioning.

01-10-2026

Chief Executive Officer KERSTEN GEERT R was awarded 2,621 Common Stock at $2.06 (~$5.4K). KERSTEN GEERT R holds 318,763 shares after the transaction.

• · Chief Executive Officer KERSTEN GEERT R was awarded 2,621 Common Stock at $2.06 (~$5.4K)